Forgot Password?
Return to Course Listing

CME: Renal Cell Carcinoma (RCC): Optimizing Pharmacotherapeutic and Interventional Management Strategies


Activity Description / Statement of Need:

In this online, self-learning activity:

Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons and is responsible for the vast majority – 85% – of all renal cancers.  With risk factors that include smoking, obesity, cadmium exposure, older age, and genetics, the five year survival rate of those afflicted with kidney cancer overall is 68%. In part because there are not any clear early symptoms associated with kidney cancer, RCC is discovered predominantly after it has already progressed to advanced stages, with the brain, bones, lungs, and liver serving as some of the most common sites of metastases. RCC’s treatment depends on its stage and size, with surgeryutilized for localized tumors and systemic therapy a mainstay of care for metastatic disease. 

RCC has many treatment options, both targeted and non-targeted. The former, including monoclonal antibodies and other forms of immunotherapy, is now a standard of care, although angiogenesis inhibition is also an area of consideration.  Emerging evidence is also suggesting ways in which biomarkers and radiographic indicators of response might shape the course of care.

Target Audience:

The following healthcare professionals: medical oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.

Commercial Support Disclosure: This activity is supported by educational grants from BTG.

Learners may participate in this activity free of charge.

Release Date: September 11, 2019 -- Expiration Date: September 11, 2021

Faculty: Nazli Dizman, MD


Introduction, Disclosures

Definition and epidemiology of RCC:

  • Statistics – snapshots and trends

Clinical Features of RCC [Learning Objective #1]:

  • Pathogenesis and the role of the immune system
  • Clinical presentation (signs and symptoms)

Emerging, immuno- and monoclonal therapy in RCC: within and beyond treatment guidelines [Learning Objectives #2, 3, 4, & 5]

  • How has the postsurgical treatment landscape changed in the last decade and where is it going?
  • Goals of therapy
  • Active surveillance vs. procedures: nephrectomy, ablation
  • Present therapies
  • Immune therapy: nivolumab, interleukin-2 (IL-2; aldesleukin)
  • Tyrosine kinase inhibitors: cabozantinib, lenvatinib, pazopanib, sunitinib, sorafenib, axitinib
  • mTOR inihibitors: temsirolimus, everolimus
  • Atezolizumab
  • Targeted therapies
  • Targeted and immunotherapy vs. conventional cytotoxic chemotherapy: mechanisms of action and impact on biochemical pathways and the cell life cycle
  • Safety profiles: immunotherapy and monoclonal antibodies vs. conventional cytotoxic chemotherapy
  • Immunotherapy and monoclonal antibodies in RCC treatment guidelines
  • Emerging therapies
  • Best practice: putting it all together
  • Patient case(s)

Patient-specific strategies

  • Combatting barriers to adherence
  • Patient, family, and caregiver engagement and education

Summary, conclusions, and best practice recap


Learning Objectives

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in RCC
  • Describe immuno- and monoclonal therapies´┐Ż mechanisms of action and the biochemical pathways they impact in RCC
  • Identify the treatment modalities currently available for management of RCC and apply them to patient cases using evidence-based medicine
  • Describe the differences in safety profiles between conventional cytotoxic, monoclonal, and immunotherapy in RCC
  • Describe methods for combatting barriers to patient care, including fostering a strong provider-patient relationship



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosure: Nazli Dizman, M.D. has no relevent financial disclosures. 


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevent financial disclosures.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting

Addressing skeletal-related events in prostate cancer

Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

Treating Oncology Patients During COVID-19